MedPath

IMM-27M

Generic Name
IMM-27M

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
HCC
Interventions
First Posted Date
2025-01-08
Last Posted Date
2025-01-08
Lead Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Target Recruit Count
108
Registration Number
NCT06764836
Locations
🇨🇳

ZhongShan Hospital Fudan University, Shanghai, Shanghai, China

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Phase 1
Recruiting
Conditions
Oncology
CTLA4 Haploinsufficiency
Interventions
First Posted Date
2022-02-11
Last Posted Date
2023-05-24
Lead Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Target Recruit Count
16
Registration Number
NCT05235438
Locations
🇨🇳

Henan Cancer Hospital, Henan, China

🇨🇳

Sun Yai-Sen Memorial Hospital,Sun Yai-Sen University, Guangzhou, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, China

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath